(IN BRIEF) Boehringer Ingelheim has licensed a pre-clinical small molecule program from Kyowa Kirin to develop a potential first-in-class therapy for autoimmune diseases, a major global health challenge affecting around 10% of the population. The deal grants Boehringer exclusive worldwide … Read the full press release
Posted in Business, Financial, Germany, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Security & Safety, Technology
Tagged autoimmune diseases, biotechnology, Boehringer Ingelheim, Boehringer Ingelheim Secures Exclusive Global Rights to Develop New Autoimmune Treatment from Kyowa Kirin, Boehringer Ingelheim Strengthens Autoimmune Disease Pipeline with Licensing Agreement from Kyowa Kirin, Carine Boustany, chronic inflammation, drug development, global health, immunology, inflammatory diseases, Kyowa Kirin, licensing agreement, pharmaceutical innovation, pre-clinical program, respiratory diseases, small molecule therapy, Takeyoshi Yamashita
(IN BRIEF) GSK has signed an exclusive global licensing agreement with Empirico Inc. for EMP-012, a first-in-class siRNA candidate currently in Phase I trials for chronic obstructive pulmonary disease (COPD). EMP-012 targets a distinct inflammatory pathway, offering potential therapeutic benefit … Read the full press release
Posted in Business, Healthcare, Investment, Pharma & Biotech, Science, Technology, United Kingdom
Tagged biologics, Chronic obstructive pulmonary disease, COPD, drug development, EMP-012, Empirico, gene expression, genetic medicine, GSK, GSK Acquires Global Rights to Empirico’s siRNA Candidate EMP-012 for Chronic Obstructive Pulmonary Disease, GSK and Empirico Partner on First-in-Class siRNA Therapy EMP-012 to Address Unmet Needs in COPD, Healthcare Innovation, inflammation, inflammation pathway, Kaivan Khavandi, licensing agreement, oligonucleotide therapeutics, Omri Gottesman, Phase I clinical trial, precision medicine, respiratory diseases, respiratory pipeline, siRNA, type 2 inflammation
(IN BRIEF) Pfizer and BioNTech have announced positive topline results from a Phase 1/2 study of their mRNA-based combination vaccine program for influenza and COVID-19. The lead formulations showed robust immune responses to influenza A, influenza B, and SARS-CoV-2 strains. … Read the full press release
Posted in Business, Environment, Financial, Germany, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Technology
Tagged Annaliesa Anderson, BioNTech, Combination Vaccine, Comirnaty, COVID-19, influenza, influenza A, influenza B, mRNA, partnership, Pfizer, Prof. Ugur Sahin, respiratory diseases, SARS-CoV-2 strains, sustainability, wellness
Sandoz gains significant capabilities and assets in medical and drug device development that target major growth opportunities in respiratory and complex generics Respiratory diseases are leading cause of death and disability and impose huge financial burden on patients worldwide Acquisition … Read the full press release
Dupixent is the first and only medicine to demonstrate positive Phase 3 results in prurigo nodularis, confirming the potential benefit of targeting IL-4 and IL-13, central drivers of type 2 inflammation, to address itch and skin lesions Data confirm results … Read the full press release
Posted in France, Healthcare, News, Pharma & Biotech, Science, Technology
Tagged asthma, atopic dermatitis, CRSwNP, dermatological diseases, dupilumab, Dupixent, extreme itch, George D. Yancopoulos, inflammatory skin disease, Naimish Patel, nodules, persistent itch, prurigo nodularis, Regeneron, respiratory diseases, skin diseases, skin lesions, unbearable itch
New study combining Esbriet (pirfenidone) and nintedanib showing similar safety profile for the combination treatment to that expected for each treatment alone A second, retrospective, post-hoc, analysis suggests that treatment with Esbriet may be associated with a reduction of multiple … Read the full press release
Posted in Healthcare, Pharma & Biotech, Switzerland
Tagged Esbriet, idiopathic pulmonary fibrosis, nintedanib, respiratory diseases, Roche, Sandra Horning MD
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions. Here you can learn more about EuropaWire’s mission, achievements, services, etc.
HOW TO GET STARTED?